August Moretti Purchases Shares of Vivani Medical

On June 24, 2026, August Moretti purchased 36,000 shares of Vivani Medical, Inc. (NasdaqCM: VANI) at an average price of $1.22 per share. This transaction was not part of a pre-planned trading program, and the total value of the purchase amounted to $43,920.

Insider Buying and Selling at Vivani Medical, Inc.

Several insiders at Vivani Medical, including August Moretti, engaged in stock purchases on June 24, 2026. Moretti bought 36,000 shares at $1.22 each. Other insiders, such as Gregg Williams and Daniel Bradbury, also acquired 36,516 shares each at the same price. These transactions were not conducted under any pre-arranged plans.

Other Institutional Activity in Vivani Medical

Vanguard Capital Management LLC opened a new position in Vivani Medical, acquiring 1,530,933 shares valued at approximately $1.53 million. Tanager Wealth Management LLP trimmed its holdings by 98,075 shares, leaving 641,085 shares worth about $641,085, a 13.3% decrease. Geode Capital Management, LLC increased its position by 138,926 shares, reaching a total of 600,578 shares valued at around $600,659, marking a 30.1% rise. Tudor Investment Corp ET Al reduced its stake by 490,060 shares, ending with 426,302 shares valued at about $426,302, a 53.5% drop. UBS Group AG significantly boosted its holdings by 331,035 shares, resulting in 337,749 shares worth approximately $337,749, a remarkable 4,930.5% increase.

Vivani Medical, Inc. Stock Down 15.8%

As of Friday, shares of Vivani Medical, Inc. (NasdaqCM: VANI) were trading near $1.20. The company has a market capitalization of approximately $98.3 million. It is not currently profitable, reflected by its lack of a meaningful P/E ratio. The stock's 52-week range spans from $0.92 to $1.92, with a 50-day moving average of $1.24 and a 200-day moving average of $1.31. Vivani Medical holds a beta of 3.289, indicating higher volatility compared to the broader market. The company maintains a strong liquidity position with a current ratio of 3.181 and a quick ratio of 3.018, despite a high debt-to-equity ratio of 95.756.

Analysts Set New Price Targets

On June 23, 2026, Lake Street initiated coverage on Vivani Medical with a "buy" rating and a price target of $4.00. HC Wainwright & Co. maintained their "buy" rating with a price target of $3.50 on April 1, 2026. Overall, the consensus among analysts is a "strong buy," with an average price target of $3.83 across three analyst opinions.

About Vivani Medical

Vivani Medical, Inc., based in Alameda, California, is a clinical-stage biopharmaceutical company specializing in the development of miniaturized and subdermal drug implants. These implants aim to improve treatment outcomes for chronic diseases. The company's NanoPortal technology is at the core of its efforts to create drug implant candidates, either independently or in collaboration with other pharmaceutical companies. Vivani's pipeline includes treatments for chronic weight management and type 2 diabetes, as well as products for veterinary applications. Dr. Adam Mendelsohn leads the company as CEO, overseeing a team of 42 employees.

Bottom Line

August Moretti's insider purchase of Vivani Medical shares highlights ongoing interest in the company's potential. Vivani Medical, with its focus on innovative drug delivery systems, continues to attract both insider and institutional attention. The company remains a speculative investment given its current lack of profitability, but analyst ratings suggest optimism about its future prospects. As always, these filings reflect past transactions and may not indicate current positions or future intentions.